Completed OBSERVATIONAL NCT05151159

Prognostic Value of Protein IMP3 Expression in Cervical Cancer

Sponsor: University of Mostar

Interventions immunohistochemical analysis with murine monoclonal antihuman antibodies IMP3

Updated 5 times since 2022 Last updated: May 9, 2023 Started: Jan 1, 2003 Primary completion: Dec 31, 2013 Completion: Dec 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Cervical Carcinoma and is currently completed. University of Mostar leads this study, which shows 5 recorded versions since 2003 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jun 2023 — Jul 2024 [monthly]

Completed

Status: Active Not Recruiting → Completed
Feb 2022 — Jun 2023 [monthly]

Active Not Recruiting
Jan 2022 — Feb 2022 [monthly]

Active Not Recruiting

First recorded

Jan 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Mostar

Data source: University of Mostar

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.